{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:05:47Z","timestamp":1790935547468,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myeloproliferative neoplasms (MPNs) are associated with recurrent activating mutations of signaling proteins such as Janus kinase 2 (JAK2). However, the actual downstream signaling events and how these alter myeloid homeostasis are poorly understood. We developed an assay to measure basal levels of phosphorylated signaling intermediates by flow cytometry during myeloid differentiation in MPN patients. Our study provides the first systematic demonstration of specific signaling events and their comparison with disease phenotype and JAK2 mutation status. We demonstrate increased basal signaling in MPN patients, which occurs in both early and later stages of myeloid differentiation. In addition, the pattern of signaling is not correlated with JAK2 mutation status and signaling intensity is poorly correlated with mutant JAK2 allele burden. In contrast, signaling differences are detected between different MPN disease phenotypes. Finally, we demonstrate that signaling can be inhibited by a JAK2-selective small molecule, but that this inhibition is not JAK2 V617F specific, because MPN patients with mutant JAK2, wild-type JAK2, and control patients were inhibited to a similar degree. Our data suggest that, in addition to JAK2 mutations, other factors contribute significantly to the MPN phenotype, results that are relevant to both the pathogenesis and therapy of MPN.<\/jats:p>","DOI":"10.1182\/blood-2011-02-335042","type":"journal-article","created":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T20:24:04Z","timestamp":1307564644000},"page":"1610-1621","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms"],"prefix":"10.1182","volume":"118","author":[{"given":"Shubha","family":"Anand","sequence":"first","affiliation":[{"name":"Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Stedham","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Gudgin","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, United Kingdom;"},{"name":"Cambridge University Foundation Hospital Trust, Cambridge, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Campbell","sequence":"additional","affiliation":[{"name":"Cambridge University Foundation Hospital Trust, Cambridge, United Kingdom; and"},{"name":"Wellcome Trust Sanger Institute, Hinxton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Beer","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, United Kingdom;"},{"name":"Cambridge University Foundation Hospital Trust, Cambridge, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, United Kingdom;"},{"name":"Cambridge University Foundation Hospital Trust, Cambridge, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J. P.","family":"Huntly","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, United Kingdom;"},{"name":"Cambridge University Foundation Hospital Trust, Cambridge, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2019111807093370900_B1","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders.","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111807093370900_B2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"9464","key":"2019111807093370900_B3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"2019111807093370900_B4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"2019111807093370900_B5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111807093370900_B6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111807093370900_B7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111807093370900_B8","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"10","key":"2019111807093370900_B9","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/leu.2008.236","article-title":"Aberrant signal transduction pathways in myeloproliferative neoplasms.","volume":"22","author":"Kota","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"2019111807093370900_B10","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0301-472X(01)00637-3","article-title":"STAT3 is constitutively active in some patients with Polycythemia rubra vera.","volume":"29","author":"R\u00f6der","year":"2001","journal-title":"Exp Hematol"},{"issue":"1","key":"2019111807093370900_B11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2007-01-069237","article-title":"Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation.","volume":"110","author":"Teofili","year":"2007","journal-title":"Blood"},{"issue":"16","key":"2019111807093370900_B12","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111807093370900_B13","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111807093370900_B14","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111807093370900_B15","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111807093370900_B16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"2019111807093370900_B17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111807093370900_B18","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"issue":"86","key":"2019111807093370900_B19","doi-asserted-by":"crossref","first-page":"pl3","DOI":"10.1126\/scisignal.286pl3","article-title":"Analysis of signaling events by dynamic phosphoflow cytometry.","volume":"2","author":"Firaguay","year":"2009","journal-title":"Sci Signal"},{"issue":"8","key":"2019111807093370900_B20","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","article-title":"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations.","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"2019111807093370900_B21","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111807093370900_B22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2004.06.028","article-title":"Single cell profiling of potentiated phospho-protein networks in cancer cells.","volume":"118","author":"Irish","year":"2004","journal-title":"Cell"},{"issue":"6","key":"2019111807093370900_B23","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/sj.leu.2404189","article-title":"BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.","volume":"20","author":"Hamilton","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"2019111807093370900_B24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccr.2008.08.014","article-title":"Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.","volume":"14","author":"Kotecha","year":"2008","journal-title":"Cancer Cell"},{"issue":"10","key":"2019111807093370900_B25","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1038\/sj.leu.2404338","article-title":"Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.","volume":"20","author":"Mesa","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"2019111807093370900_B26","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1634\/stemcells.2007-0899","article-title":"Downregulation of signal transducer and activator of transcription 5 (STAT5) in CD34+ cells promotes megakaryocytic development, whereas activation of STAT5 drives erythropoiesis.","volume":"26","author":"Olthof","year":"2008","journal-title":"Stem Cells"},{"issue":"13","key":"2019111807093370900_B27","doi-asserted-by":"crossref","first-page":"13163","DOI":"10.1074\/jbc.M413461200","article-title":"GATA transcription factors inhibit cytokine-dependent growth and survival of a hematopoietic cell line through the inhibition of STAT3 activity.","volume":"280","author":"Ezoe","year":"2005","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111807093370900_B28","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1182\/blood-2006-08-040352","article-title":"Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis.","volume":"109","author":"Jenkins","year":"2007","journal-title":"Blood"},{"issue":"23","key":"2019111807093370900_B29","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111807093370900_B30","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia.","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2019111807093370900_B31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors.","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"issue":"7","key":"2019111807093370900_B32","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/0092-8674(91)90011-M","article-title":"Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene.","volume":"65","author":"Tybulewicz","year":"1991","journal-title":"Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/6\/1610\/1346137\/zh803211001610.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/6\/1610\/1346137\/zh803211001610.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:12:23Z","timestamp":1574061143000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/6\/1610\/29103\/Increased-basal-intracellular-signaling-patterns"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-02-335042","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,11]]}}}